Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 17, 2025 04:57 ET | Source: Research and Markets

Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers

Dublin, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Engineered Multispecific antibodies" report has been added to ResearchAndMarkets.com's offering.Engineered multispecific...
January 13, 2025 06:40 ET | Source: Research and Markets

Biotherapeutics Market Insights 2025, Analysis and Forecast to 2030: Insulin Demand Soars Amid Diabetes Epidemic, Sees $40 Billion Opportunity

Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Biotherapeutics Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type" report...
January 08, 2025 11:42 ET | Source: Research and Markets

Antibodies Contract Manufacturing Market Research 2024 with Global Long-term Forecasts to 2035: Expansion of Emerging Markets, Personalized Medicine, Therapeutic Antibodies Demand Fueling Growth

Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Antibodies Contract Manufacturing Market by Product, by Source, by End-User, and By Region" report has been added to ResearchAndMarkets.com's...
December 20, 2024 10:05 ET | Source: Research and Markets

8MM Respiratory Syncytial Virus Prophylaxis Market Drug Analysis Report: Prophylactic Options to Continue to Diversify Due to Strength of Late-Stage Pipeline - Forecast to 2030

Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus Prophylaxis: Eight-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's...
December 11, 2024 06:25 ET | Source: Research and Markets

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's...
November 26, 2024 06:29 ET | Source: Research and Markets

Monoclonal Antibody Collaboration and Licensing Analysis Report 2024 with Directory of 639 Deals Signed Since 2019 by Company A-Z, Deal Type and Therapeutic Target

Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and...
November 22, 2024 05:54 ET | Source: Research and Markets

$55.7 Billion Biopharmaceutical Fermentation Systems Market Opportunities and Strategies to 2033: Development of New Bioreactors to Enhance Single-Use Upstream Operations, New Technology Developments

Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceutical Fermentation Systems Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering. The...
November 19, 2024 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
November 07, 2024 09:35 ET | Source: Research and Markets

CC Chemokine Receptor Type 5 Market Research Report 2024

Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC chemokine receptor type 5 market...
November 07, 2024 07:00 ET | Source: SynOx Therapeutics Limited

SynOx Therapeutics Further Strengthens Executive Team with Appointments of U.S.-Based Chief Medical Officer and Chief Commercial Officer

Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company’s Presence in the U.S. Seasoned Team to Drive Forward Pivotal Phase 3 Trial of Emactuzumab in Patients...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right